Background: To discover a novel antidepressant-like effect and anticonvulsant
compound, seventeen new 2-oxo-3-phenyliminoindolin-1-Nphenylacetamide
compounds were synthesized and screened for the antidepressant
activity and anticonvulsant effects.
Method: 2-oxo-3-phenyliminoindolin-1-N-phenylacetamide derivatives were synthesized
with indoline-2, 3-dione as the starting material, through a nucleophilic
substitution reaction and a nucleophilic addition-elimination reaction. The target
derivatives 2a-2q were evaluated the antidepressant-like activity using the FST,
TST, and evaluated anticonvulsant effect by MES test. The main monoamine neurotransmitters
and their metabolites in mouse brain regions were also simultaneously
determined by HPLC-ECD.
Results: It was observed that 13 compounds showed significant reductions in the immobility time in
the FST at a concentration of 50 mg/kg. Compound 2b was found to have the most potent antidepressant
activity in the FST and the TST for 30 min after treatment. Compound 2b significantly increased
the concentrations of the main neurotransmitters 5-HT, NE and the metabolite (5-HIAA,
suggesting that the effects of compound 2b may be mediated through these neurotransmitters. As assessed
using maximal electroshock, 13 compounds showed the anticonvulsant effects administered at
the concentration levels of 100 or 300 mg/kg. Compound 2b showed anticonvulsant effect. Compound
2b could potentially be used as adjuncts of the antidepressants to treat depression in patients
Conclusion: In conclusion, compound 2b produced significant antidepressant-like activity and the mechanism
of action may be due to increased 5-HT and NE in the mouse. Compound 2b showed more anticonvulsant
effect. Compound 2b could potentially be used as adjuncts of the antidepressants to treat depression in
patients with epilepsy.